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Abstract.  We have investigated the sorting and pack- 
aging of secretory proteins into secretory granules by 
an immunological approach.  An mAb against 
secretogranin I (chromogranin  B), a  secretory protein 
costored with various peptide hormones and neuropep- 
tides in secretory granules of many endocrine cells 
and neurons,  was expressed by microinjection of its 
mRNA into the secretogranin I-producing cell line 
PC12.  An mAb against the G  protein of vesicular sto- 
matitis virus-i.e.,  against an antigen not present in 
PC12 cells-was expressed as a control.  The intracel- 
lular localization and the secretion of the antibodies 
was studied by double-labeling immunofluorescence 
using the conventional and the confocal microscope, as 
well as by pulse-chase experiments.  The secretogranin 
I antibody, like the control antibody, was transported 
along the secretory pathway to the Golgi complex. 
However, in contrast to the control antibody, which 
was secreted via the constitutive pathway,  the 
secretogranin I antibody formed an immunocomplex 
with secretogranin I,  was packaged into secretory 
granules,  and was released by regulated exocytosis. 
Our results show that a constitutive secretory protein, 
unaltered by genetic engineering,  can be diverted to 
the regulated pathway of secretion by its protein-pro- 
tein interaction  with a  regulated secretory protein.  The 
data also provide the basis for immunologically study- 
ing the role of luminally exposed protein domains in 
the biogenesis and function of regulated secretory 
vesicles. 
OME eukaryotic cells- such as exocrine, endocrine, and 
neuronal  cells-contain at least two distinct  pathways 
of protein secretion.  In the constitutive pathway, which 
exists in these and essentially all other eukaryotic cells, cer- 
tain secretory proteins (e.g., components of the extracellular 
matrix) are transported to the cell surface without intracellu- 
lar storage  and are released without external  regulation  of 
exocytosis. In the regulated pathway, which is a characteristic 
feature  of exocrine,  endocrine, and neuronal  cells, certain 
other secretory proteins (e.g., zymogens, peptide hormones, 
and neuropeptides)  are packaged into secretory storage gran- 
ules from which they are exocytosed in a regulated  manner 
(for reviews see Burgess and Kelly, 1987; Pfeffer and Roth- 
man,  1987). 
The specific secretion of constitutive  and regulated  secre- 
tory proteins by the same cell via the constitutive  and regu- 
lated pathway, respectively,  involves the segregation of these 
proteins from each other. Recently, it has been suggested that 
the packaging  of regulated  secretory proteins into secretory 
granules is a signal-mediated process which is dominant over 
the post-Golgi route taken by constitutive  secretory proteins 
(Burgess and Kelly, 1987; Pfeffer and Rothman,  1987). The 
only direct piece of evidence in support of this concept is the 
observation that  a chimeric  fusion protein composed of a 
regulated  secretory protein (growth  hormone) and the ec- 
todomain of a membrane protein (G protein of vesicular sto- 
matitis  virus [VSV-G]  ~ lacking  the transmembrane  and cy- 
toplasmic domains) was packaged into secretory granules of 
AtT-20 cells (Moore and Kelly,  1986). However, the possi- 
bility cannot be excluded that the truncation  of VSV-G and 
its fusion to growth hormone may have inactivated structural 
information  that otherwise would have resulted in the trans- 
port of the fusion protein to the cell surface via the constitu- 
tive pathway. 
We therefore decided to investigate secretory protein sort- 
ing by an alternative approach that would not have the prob- 
lems inherent  in experiments  with chimeric fusion proteins 
and that could complement the latter studies.  This approach 
was to study the intracellular  traffic of a noncovalent complex 
consisting of a regulated secretory protein and a constitutive 
secretory protein  unmodified  by genetic engineering.  For a 
regulated  secretory protein we chose secretogranin  I (SgI), 
also called chromogranin  B (Eiden  et al.,  1987), a protein 
packaged into secretory granules  of a wide variety of endo- 
1.  Abbreviations  used  in  this  paper:  NGF,  nerve  growth  factor;  Sgl, 
secretogranin I; SglI, secretogranin II; VSV-G, G protein of vesicular sto- 
matitis virus. 
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et al., 1985b).  For a constitutive secretory protein we chose 
a monoclonal anti-SgI antibody, mAbs have previously been 
expressed  in  nonlymphoid constitutive secretory cells by 
microinjection of their mRNA where they have been shown 
to form immunocomplexes in the secretory pathway with 
their respective antigens (Valle et al., 1982; Burke and War- 
ren, 1984). We therefore expected that the monoclonal anti- 
SgI antibody, when expressed in neuroendocrine cells pro- 
ducing SgI, should form an immunocomplex with SgI. If this 
immunocomplex were to be packaged into secretory gran- 
ules, this would be direct evidence for the dominant targeting 
information present in regulated secretory proteins. In addi- 
tion, the packaging of a complex of an antibody and a secre- 
tory granule protein into secretory granules would provide 
the basis for studying the functional role of luminally exposed 
epitopes of secretory granule proteins by antibody neutral- 
ization, analogous to previous work on a Golgi-resident pro- 
tein (Burke and Warren, 1984).  Here we show that a mono- 
clonal anti-SgI antibody, in contrast to a control antibody, is 
diverted from the constitutive pathway of secretion and pack- 
aged, in an immunocomplex with SgI, into secretory gran- 
ules of the neuroendocrine cell line PC12. 
Materials and Methods 
Antibodies 
mAbs against rat SgI were raised as follows. [35S]Sulfate-labeled  secreto- 
granins were purified from PC12 cells by heat treatment, DEAE-Sephacel 
chromatography,  and two-dimensional PAGE  as described (Rosa et al., 
1985b;  Benedum et al.,  1987).  After electrophoresis, proteins were trans- 
ferred onto nitroceUulose filters (Rosa et al., 1985a) and the position of SgI 
was revealed by autoradiography. Pieces of the nitrocellulose filter contain- 
ing pure SgI (either pl13  or p105;  Lee and Huttner,  1983;  Rosa et al., 
1985b;  "o7 #g as determined by Coomassie blue staining of a duplicate gel) 
were implanted into the peritoneal cavity of 6-wk-old BALB/c mice. 1 mo 
later,  the mice were boostered with "~5 ~g of pure SgI that was prepared 
as before except that the filter pieces were crushed to a fine powder under 
liquid N2, resuspended in PBS, pH 7.4,  and injected intraperitoneally. Af- 
ter 15 d, sera from the mice were collected and tested by immunoblotting 
using total homogenate of PCI2 (see below). A mouse producing antibodies 
against SgI was then boostered intraperitoneally on two consecutive days 
with 40 ttg of Sgl that was partially purified through heat treatment and 
DEAE chromatography, precipitated with acetone, and solubilized in PBS 
containing 0.025%  SDS. 2 d after the last injection, spleen cells from that 
mouse were fused with SP 2/01 myeloma cells, and hybridomas were grown 
according to standard procedures (Ochiai et al., 1982; Goding, 1983).  Hy- 
bridoma supernatants were screened by immunoblotting of total PCI2 cell 
protein, and clones producing antibodies against SgI were subcloned under 
microscopic observation (Ochiai et al.,  1982).  The hybridoma clone used 
in this study is referred to as 219.6. The immunoglobulin class of the mAbs 
was determined by dot-blot analysis of hybridoma supernatants spotted on 
nitrocellulose filters, using the immunoblotting protocol described below 
and antibodies specific for the different mouse antibody subclasses (Nordic 
Immunological Reagents, Bochum, FRG).  Ascites fluid was produced in 
BALB/c mice, and IgG was purified by ammonium sulfate precipitation fol- 
lowed by ion exchange chromatography as described by Goding (1983). 
The hybridoma producing an antibody against VSV-G was the P5D4 line 
described by Kreis (1986)  and was a kind gift of Dr. T.  Kreis (European 
Molecular Biology Laboratory, Heidelberg, FRG). 
Polyclonal anti-rat SgI antibody and anti-rat Secretogranin II (SgII) anti- 
body (Rosa et al.,  1985b) were affinity purified as described (Benedum et 
al., 1987).  Polyclonal anti-VSV-G antibody and polyclonal anti-mouse IgG 
antiserum were a gift of Drs. K. Simons and S. Tooze (European Molecular 
Biology Laboratory, Heidelberg, FRG), respectively. Polyclonal anti-Golgi 
complex antibody (Louvard et al.,  1982) was a gift of Dr. B. Burke (then 
at European Molecular Biology Laboratory, Heidelberg, FRG). The puri- 
fied mAb against p38/synaptophysin was the clone C7.3 described previ- 
ously (Jahn et al., 1985) and was a gift of Drs. R. Jahn (Max Planck Institute 
for Psychiatry,  Martinsried, FRG) and P. Greengard (Rockefeller Univer- 
sity, New York). Polyclonal antibody against a glycoprotein (Igpl20) of the 
lysosomal membrane (Lewis et al., 1985) was a gift of Dr. I. Mellman (Yale 
University, New Haven, CT). Goat anti-mouse IgG antibody conjugated to 
either fluorescein or rhodamine and goat anti-rabbit IgG antibody con- 
jugated to fluorescein were gifts of Dr. T. Kreis. Goat anti-rabbit IgG anti- 
body conjugated to rhodamime was purchased from Biosys S.A.  (Com- 
pi6gne, France). 
Characterization of mAb 219.6 
PC12  cells (clone II-251)  were grown in DME  supplemented with  10% 
horse serum and 5% FCS. For immunoblotting, a PC12 cell total homoge- 
hate (Lee and Huttner,  1983) and a human pheochromocytoma chromaflin 
granule  fraction,  prepared as described for bovine chromaffin granules 
(Trifaro and  Duerr,  1976) with minor modifications, were separated by 
SDS-PAGE, and the proteins were transferred onto nitrocellulose filters as 
described (Rosa et al.,  1985a).  The filters were incubated for 18 h at 4°C 
in immunoblotting buffer (PBS containing 8% BSA) followed by incubation 
for 2 h at room temperature either in undiluted hybridoma supernatant con- 
taining l0 mM Hepes or mice sera diluted 1:100 in immunoblotting buffer 
containing 0.3 % Tween 20. After several washes in PBS-Tween, filters were 
incubated for 45 rain with peroxidase conjugated to goat anti-mouse IgG 
and IgM antibodies (Jackson Immuno Research Laboratories Inc., Avon- 
dale, PA) in immunoblotting buffer-Tweem  washed with PBS-Tween, devel- 
oped with 0.5  mg/ml 3,Y-diaminobenzidine and 0.03%  HzO2 in 50 mM 
Tris-HCl, pH 7.5, and finally washed with water to terminate the reaction. 
For immunoprecipitation experiments, PC12 cells were preincubated for 
1 h in tyrosine-free DME supplemented with serum dialyzed against PBS 
with or without  10  -6 M  monensin (Calbiochem-Behring GmbH,  Frank- 
furt, FRG). Cells were then labeled for 4 h with 50 #Ci/ml of L-[2, 3, 5, 
6-3H] tyrosine ("°3 TBq/mmol; Amersham Buchler GmbH, Braunschweig, 
FRG), washed with PBS, solubilized in immunoprecipitation buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.3 % Tween 20) containing 
1 mM PMSE sonicated, and centrifuged for 1 min in a centrifuge (Eppen- 
doff; Brinkmann Instruments Co., Westbury,  NY). 50/zl of the cleared ly- 
sate (80-150 #g protein) was diluted I:10 with immunoprecipitation buffer 
and incubated overnight at 4°C with either l  ml of hybridoma supernatant 
or 15 #l of ascites fluid followed by a 15-min incubation with 75 #l (packed 
gel) of goat anti-mouse IgG antibodies coupled to agarose (A-6531; Sigma 
Chemical GmbH, Munich, FRG)~ After several washes with immunopre- 
cipitation buffer,  the  immunocomplex was solubi[ized from the agarose 
beads by boiling in Laemmli sample buffer and analyzed by SDS-PAGE fol- 
lowed by fluorography (Lee and Huttner,  1983).  In some experiments, im- 
munoprecipitation was carried out at pH 6 instead of pH 7.5 by replacing 
the Tris-HCl with 50 mM morpholinoethanesulfonic acid-NaOH, pH 6, in 
the dilution step and thereafter. 
Isolation of Polyadenylated RNAs 
219.6 and P5D4 hybridoma cells were grown to a density of l06 cells/ml 
in glass spinner culture vessels in RPMI 1640 medium supplemented with 
10%  FCS,  4.5  g/liter glucose,  and  penicillin/streptomycin.  1  h  before 
homogenization~  l0 #g/ml of cycloheximide (Sigma Chemical GmbH) was 
added to the medium. Microsomes were prepared from 5.5  ×  109 cells as 
described (Burke and Warren,  1984),  except that the cell homogenate re- 
ceived additional MgCI2 to a final concentration of 5 mM before the cen- 
trifugation steps. RNA was isolated from the microsomal pellet by a modi- 
fication of previously published procedures (Cox,  1968;  Chirgwin et al., 
1979).  The microsomal pellet was homogenized in 6 M guanidine hydro- 
chloride, 10 mM DTT, 25 mM EDTA, pH 7, the homogenate was adjusted 
to 0.1 M potassium acetate, pH 5, and RNA was precipitated after addition 
of 0.5 vol ethanol at -20°C. The precipitate was subjected to two additional 
cycles of guanidine hydrochloride suspension and ethanol precipitation as 
above.  The final  precipitate was taken up in 0.1  M Tris-HCl, pH 8.9, 0.1 
M NaCl, 1 mM EDTA, 1% SDS, incubated for 10 min at 37°C, mixed with 
an equal volume of phenol/chloroform/isoamyl  alcohol (50:50:1),  and RNA 
was precipitated from the aqueous phase by addition of sodium acetate, pH 
5, to a final concentration of 0.2 M and 2 vol 95% ethanol at  -20°C. The 
pellet was dissolved in water, the solution was adjusted to 3 M sodium ace- 
tate, pH 6, and RNA was precipitaaxt at -16 to -20°C. The precipitated RNA 
was washed with 75% ethanol. Poly(A)+RNA was purified by affinity chro- 
matography on an oligo-(dT)-cellulose column (Collaborative Research, 
Inc., Waltham, MA) as described (Aviv and Leder, 1972),  except that the 
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Poly(A)+RNA was then precipitated after addition of 0.2 M potassium ace- 
tate, pH 5, and 2 vol ethanol; the precipitate was washed with 75% ethanol 
and redissolved in water at a final concentration of 1 mg/ml for microinjec- 
tion. The mRNA coding for heavy and light chain of IgG in poly(A)+RNA 
preparations was quantitated by in vitro translation using a reticulocyte ly- 
sate system in the presence of L-[35S]methionine  (NEK-001  translation kit; 
New England Nuclear, GmbH, Dreieich, FRG) followed by immunoprecip- 
itation of heavy and light chain, SDS-PAGE, and determination of incorpo- 
rated radioactivity. 
Cell Culture and Microinjection 
PCI2 cells were plated onto either poly(L)lysine- or poly(D,L)ornithine- 
coated coverslips and grown either for 1 d in the absence of nerve growth 
factor (NGF) or for 2-3 d in the presence of 200 ng/ml of NGF (a gift from 
Dis. Y-A. Barde and H. Thoenen, Max Planck Institute for Psychiatry, Mar- 
tinsried, FRG). Immediately before microinjection, 10 mM Hepes, pH 7.4, 
was added to stabilize the pH of the medium during microinjection. 
Cells were microinjected (1  nag poly(A)+RNA/ml water) at room tem- 
perature using the automated capillary microinjection system with com- 
puter-controlled positioning of the cells and the capillary (Ansorge and Pep- 
perkok, 1988). With this system, coordinates of  the microinjected cells were 
stored in the computer, allowing their precise retrieval and hence a reliable 
statistical analysis of the results (Pepperkok et al., 1988).  Depending on the 
experiment, 150-1,000  cells were injected per coverslip in  10-30 min. 
After microinjection, dishes received fresh DME supplemented with se- 
rum and containing penicillin/streptomycin before being returned to the in- 
cubator for the indicated times. In some experiments, dishes received 10 
mM ammonium chloride after microinjection followed by an 18-h incuba- 
tion. In other experiments, dishes maintained for 18 h after microinjection 
were incubated for 9 rain in release medium (Meldolesi et al., 1983) either 
with  or  without  3  nM  ot-latrotoxin  purified  from  female black  widow 
spiders, Latrodectus mactans tredicimguttatus (Meldolesi, 1982;  a gift of 
Dr. J. Meldolesi, University of Milan, Milan, Italy). After incubation under 
these various conditions, cells were fixed and analyzed by immunofluores- 
cence as described below. 
Pulse-Chase Labeling of  lgG Expressed in 
Microinjected PC12 Cells 
Approximately 3,000 PC12 cells were plated on 2-mm  2 pieces of coverslips 
coated with poly(L)lysine and grown overnight in 96-well plates in 50/~l 
of DME supplemented with serum.  For microinjection, coverslips were 
carefully transferred to  3.5-cm dishes containing Hepes-buffered DME. 
About 1,000 cells per coverslip were microinjected as described above. Af- 
ter microinjection, coverslips were put back  into 96-well plates and  in- 
cubated in 50 td of methionine-free DME supplemented with 1% dialyzed 
horse serum and 0.5 % dialyzed FCS. Noninjected control coverslips were 
directly transferred to 96-well plates containing the latter medium. After 3 h, 
the medium was replaced with 50 ~1 of methionine- and KCI-free DME con- 
taining 5 mCi/ml of L-[35S]methionine  ("~30 TBq/mmol, Amersham Buch- 
ler GmbH) and 7 mM potassium acetate (from the [35S]methionine  stock). 
The cells were labeled for 1 h, and the labeling medium was removed and 
replaced with chase medium (DME containing a double concentration of 
methionine and supplemented with 1% horse serum and 0.5% FCS). After 
4 h of chase, the chase medium was collected, spun for 5 rain in a centrifuge 
(Eppendorf; Brinkmann Instruments Co.), adjusted to 0.3 % Triton X-100, 
and subjected to immunoprecipitation as described below.  The cells were 
washed with cold PBS, solubilized in 50 ~tl of 50 mM Tris-HC1,  pH 7, con- 
taining 0.3 % Triton X-100, 150 mM NaCI, 5 mM EDTA, 1 mM PMSE spun 
for I rain in a centrifuge (Eppendorf; Brinkmann Instruments Co.), and also 
subjected to immunoprecipitation. 
Labeled IgG was immunoprecipitated by incubation for 15 rain with 25 
ftl (packed gel) of goat anti-mouse IgG coupled to agarose. After several 
washes with 50 mM Tris-HCl, pH 7, 0.3% Triton X-100, 450 mM NaCl, 
5 mM EDTA,  the immune,  complex was solubilized under a  nonreducing 
condition by boiling in Laemmli sample buffer without 2-mereaptoethanol 
and subjected to nonreducing SDS-PAGE (6% polyacrylamide) followed by 
fluorography (Lee and Huttner,  1983).  For reelectropboresis under reduc- 
ing conditions, dry gel pieces from the IgG region were excised from the 
nonreducing gels, reswollen in 30%  methanol and  10%  acidic acid to re- 
move the salicylate from the fluorography, rinsed in water, and dried. The 
gel pieces were then reswollen for 15 min in 400 #l of Laemmli sample 
buffer containing 5 % 2-mereaptoethanol, boiled in this buffer for 2 rain fol- 
lowed by immediate removal of excess buffer, and placed in the slots of a 
12%  SDS-polyacrylamide gel followed by electrophoresis and fluorogra- 
phy. The heavy chain region of the fluorograms was scanned densitometri- 
cally using an ultroscan XL (LKB Instruments, Inc., Gaithersburg, MD). 
Absorbance values from the corresponding region of samples from nonin- 
jected cells of the same fluorograms were subtracted as background. 
lmmunofluorescence 
For double immunofluorescence, cells were washed with PBS, fixed for 30 
min at room temperature with 3 % paraformaldehyde in 120 mM phosphate 
buffer, pH 7.4, permeabilized for 5 rain in PBS containing 0.3% Triton X-100, 
and quenched for 30 min with 0.1 M glycine-Tris, pH 7.5. Cells were then 
incubated for 1.5 h in 20 mM phosphate buffer, pH 7.3, 450 mM NaCI, 0.2 % 
gelatine (immunofluorescence buffer) containing goat anti-mouse IgG anti- 
body coupled to rhodamine. After several washes in immunofluorescence 
buffer, cells were incubated for 2 h with the indicated polyclonal rabbit or 
monoclonal mouse antibodies against either Sgl, SgII, p38/synaptophysin, 
or the Golgi complex. In the case of immunostaining for Igpl20,  PBS- 
washed PC12 cells were fixed for 5 min in methanol at -20°C, washed with 
PBS and immunofluorescence buffer,  and incubated with poyclonal rabbit 
anti-rat lgpl20. All coverslips were then washed again and incubated in im- 
munofluorescence buffer containing the appropriate goat anti-rabbit IgG or 
anti-mouse IgG secondary antibodies coupled to fluorescein. Coverslips 
were sequentially rinsed in immunofluorescence buffer, PBS, and distilled 
water and finally mounted in Mowiol 4.88 (Calbiochem-Behring GmbH). 
The cells were observed using a photomicroscope (Ultraphot; Carl Zeiss, 
Inc.,  Thornwood, NY) equipped with epifluorescence optics and photo- 
graphed using Tmax negatives (Eastman Kodak Co., Rochester, NY). 
In some experiments, cells after microinjection of 219.6 mRNA were im- 
munostained with mAb 219.6 IgGs purified from ascites and coupled to 
rhodamine (Brandtzaeg,  1973). 
Quantitation oflgG expression was performed by counting all PCl2 cells 
immunostained for IgG on a coverslip and comparing the number obtained 
with that of the cells microinjected on this coverslip as recorded by the com- 
puter. 
Reverse Immunostaining 
The presence of monoclonal IgGs expressed in microinjected PC12 cells 
and the state of occupancy of their antigen-binding sites were investigated 
by a double-immunostaining procedure which involved the use of anti-lgG 
antibody and the relevant antigen, referred to as "reverse immunostaining" 
PCI2  cells microinjected with either 219.6 or P5D4 mRNA were fixed, 
quenched, and permeabilized as described above. Coverslips were then in- 
cubated for 3 h in  100 t~l of immunofluorescence buffer containing either 
"~0.12 #g of (a) parially purified SgI (SgI purified from PC12 cells through 
heat treatment and DEAE chromatography [Rosa et al.,  1985b;  Benedum 
et  al.,  1987])  conjugated  to  rhodamine  according  to  the  procedure of 
Brandtzaeg (1973);  or (b) partially purified VSV-G (VSV solubilized in 10 
/~l of 1% Triton X-100 in PBS before 10-fold dilution with immunofluores- 
cence buffer, equivalent to •0.03  ~g of G protein as determined by dot-blot 
analysis). PCI2 cells injected with 219.6 mRNA were then washed in im- 
munofluorescence buffer,  incubated with immunofluorescence buffer con- 
mining goat anti-mouse IgG antibody coupled to fluorescein, washed again, 
and mounted. PC12 cells injected with P5D4 mRNA were then washed in 
immunofluorescence buffer,  incubated with  rabbit anti-VSV-G antibody, 
washed, incubated simultaneously with goat anti-rabbit IgG antibody cou- 
pled to rhodamine and goat anti-mouse IgG antibody coupled to fluores- 
cein, washed again, and mounted. 
219.6 and P5D4 hybridoma cells, plated on poly(L)lysine-coated cover- 
slips, were also subjected to reverse immunostaining as described above, ex- 
cept that the  incubation with goat anti-mouse IgG antibody coupled to 
fluorescein was omitted; separate coverslips were used to detect the endoge- 
nous monoclonal IgG with goat anti-mouse IgG coupled to rhodamine. 
Confocal Fluorescence Microscopy 
Configuration  of the Confocal Fluorescence  Microscope.  The configura- 
tion of  the confocal microscope used in the present study has been described 
in detail elsewhere (S~lzer et ai.,  1989).  The instrument was operated in 
the epifluorescence mode. Fluorescein and rhodamine were excited with the 
blue (476.5  nm) and green (514.5  nm) lines, respectively, of an argon ion 
laser. A combination of  the dichroic mirror from a K2 PIoemopak (E. Leitz, 
Rosa et al. Rerouting of Antibody to Secretory Granules  19 Figure 1.  Characterization of mAb 219.6  against SgI. For immunoblotting, the total homogenate of PCI2 cells ('ol00/tg of protein) and 
a chromatfin granule fraction of a human pheochromocytoma (h. PHEO, "o30/tg of protein) were immunolabeled with unconditioned cell 
culture medium (lanes 1 and 3) or cell culture medium conditioned by 219.6  hybridoma cells (lanes 2  and 4),  followed by peroxidase. 
Arrowheads indicate SgI. The immunolabeled bands with faster electrophoretic mobilities than SgI correspond to known proteolytic frag- 
ments of SgI formed in secretory granules in vivo (Rosa et al., 1985b). Molecular mass standards are in kilodaltons. For immunoprecipita- 
tion: (lane 5,  TH) Total homogenate ('ol00 #g of protein) of [3H]tyrosine-labeled PC12 cells; (lane 6, 219.6) an immunoprecipitate from 
this homogenate using 219.6  hybridoma medium; and (lane 7,  C) an immunoprecipitate from this homogenate using hybridoma medium 
containing  a  control  IgG1  directed  against  ¢x-actinin  of Dictyostelium  discoideum.  (Lane  8)  Immunoprecipitation  from  [3H]tyrosine- 
labeled PC12 cells (,o80/zg of protein) using mAb 219.6  (15/d of ascites) at the standard pH (pH 7.5) or (lane 9) at pH 6. (Lane 10,  TH) 
Total homogenate (,o50/~g of protein) of PC12 cells labeled with [3H]tyrosine in the presence of monensin; (lane 11, 219.6) an immuno- 
precipitate from this homogenate using mAb 219.6  (15/~1 of ascites). Samples were analyzed by SDS-PAGE in 7 or 10% polyacrylamide 
gels. Fluorograms of the gels are shown.  Arrowheads  indicate SgI. Molecular mass standards  are in kD. 
Inc., Wetzlar, FRG) and an OG515 cut-off filter (Schott, Mainz, FRG) was 
used when observing the fluorescein signal; the dichroic mirror of an N2 
Ploemopak (E. Leitz, Inc.) and OG530 and OG550 cut-off filters (Schott) 
were used when observing rhodamine. The microscope was equipped with 
a  100x/1.32  objective (NPL Fluotar;  E. Leitz,  Inc.).  The detector was a 
photomultiplier (R1463-01; Hamamatsu Photonics K. K., Hamamatsu City, 
Japan).  The pinhole in front of the detector had a size of 50 ~tm (1.22 × 
[0.5/zm/1.32] ×  100 = 46 ~,m), which was optimal for the present configu- 
ration of  the microscope. A single mirror mounted on a turnable galvanome- 
ter moved the light spot in the plane of the object. The movement along the 
optical axis was accomplished by moving the objective of the microscope 
up and down (Stelzer et al., 1989). Analog electronics were used to drive 
the scan system in either a horizontal x/y- or a vertical x/z-plane,  while a 
computer (VME-based 68010 microcomputer; ELTEC, Mainz, FRG) moni- 
tored  the intensity detected  by the photomultiplier  as a  function  of the 
three-dimensional position of the light spot in the object. The sample was 
illuminated  only while intensities  were  recorded.  For this  purpose,  an 
acoustooptical  modulator  driven  by the movement of the galvanometer 
deflected the beam off the sample outside the detection window. 
Sam/de Preparat/on. The same samples analyzed by double immunoflu- 
orescence in the conventional microscope were used for observation in the 
confocal microscope. 
Double Immunofluorescence.  The double inununofluorescence experi- 
ments  were  performed  by  running  the  laser  (model  2020-05;  Spectra- 
Physics,  Darmstadt,  FRG)  in  single  line and  switching back  and  forth 
between the 476.5- and the 514.5-nm lines. The cells to be analyzed had 
previously been selected by using a conventional microscope. The fluores- 
cein signal was observed first. The laser line, the dichroic mirror, and the 
cut-off filter were then changed and the rhodamine signal was observed with- 
out further realignment of the microscope. In a previous set of experiments, 
PCI2 cells double  immunostained  for the Golgi complex  and  secretory 
granules using rhodamine- and fluorescein-conjogated secondary antibody, 
respectively, had been used to choose the appropriate filters and to establish 
the above conditions that gave optimal discrimination  between these two 
distinct immunofluorescence patterns~ 
Opt/ca/Sect/ons. Z series of x/y-images were recorded with intervals of 
0.3 and 0.5 ~m along the optical axis. These intervals conformed with the 
depth discrimination along the optical axis of ~0.4 ~m full width, half max- 
imum (Wijnaendts-van-Resandt et al., 1985; Stelzer et al., 1989) and guar- 
anteed minimum overlap. Smaller intervals were avoided since they could 
increase the photoinduced damage to the object. 
Images and Photographs.  Only the high voltage supply of the photomul- 
tiplier could be varied. The gain of the amplifier as well as its offset were 
fixed. The high voltage supply of the photomultiplier  was adjusted to the 
available amount of light and great care was taken that the analog-to-digital 
converter was operated in the correct range. As a consequence, the intensity 
covered a window of,,o 245 of  the 256 available grey levels. All images were 
stored on the computer. Photographs of the images were taken from a black 
and white monitor on 50 ASA Ilford Pan F film (Ilford GmbH, Nen-lsen- 
burg,  FRG) (van Meer et al.,  1987). 
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Laser Microscope. Every image recorded by the confocal microscope con- 
sisted of 512  x  512 pixels, each capable of storing 256 grey levels. The in- 
tensity was linear with the pixel value. The high voltage defining the gain 
of the photomultiplier had to be set carefully to avoid saturation of the am- 
plifier. The lateral resolution in the configuration was better than 200 nm. 
A typical image with a field size of 3,600 #m  e consisted therefore of well- 
resolved, oversampled pixels. The discrimination against out-of-focus light, 
defined as the distance from the fluorophore at which the intensity dropped 
to 50% of its maximum value, was •0.2  t~m. Images recorded with a spac- 
ing of  0.5 #m along the optical axis showed almost no overlapping informa- 
tion. The pixel values represented an average of four accesses per pixel. No 
further image processing/filtering was performed. Photographs of images 
obtained with the confocal microscope lost quantitative information since 
it was not possible to push the 256 different grey levels into the *40 grey 
tones on a photographic print. 
Results 
The following  approach was taken  to express an antibody 
directed against  a  secretory granule  matrix protein  in the 
secretory pathway of cells capable of forming secretory gran- 
ules:  (a) the generation  of an mAb against SgI, a secretory 
protein found in secretory granules of many endocrine cells 
and neurons;  (b) the isolation ofmRNA coding for the heavy 
and light chains of the anti-SgI antibody from the hybridoma 
cells producing this antibody; and (c) the microinjection of 
this mRNA into PC12 cells, a neuroendocrine cell line that 
produces SgI and packages it into secretory granules. 
Isolation and Characterization of  an mAb against Sgl 
Mouse mAbs were raised against rat SgI, purified from PC12 
cells by heat treatment, ion-exchange chromatography,  two- 
dimensional  PAGE (Rosa et al.,  1985b;  Benedum et al., 
1987), and immobilized on nitrocellulose  filters. Character- 
ization of the hybridoma clones by immunoblotting  of total 
PC12 cell protein revealed  two mAbs that specifically  rec- 
ognized rat SgI. One of these, referred to as mAb 219.6, rec- 
ognized  not only rat  but also human SgI,  indicating  con- 
servation  of the epitope (Fig.  1, lanes 2 and 4). This mAb 
recognized SgI under a variety of conditions  relevant for the 
subsequent  experiments.  First,  mAb  219.6 specifically 
bound  to  nondenatured  SgI  in  mild  immunoprecipitation 
conditions (Fig.  1, lane 6).  Second, it immunoprecipitated 
not only the mature,  posttranslationally  modified  form of 
SgI,  but also both SgI from monensin-treated  PC12  cells 
(which lack posttranslational  modifications  such as phos- 
phorylation and sulfation;  Lee and Huttner,  1985; Rosa, P., 
and W. B. Huttner,  unpublished data)  (Fig.  1, lane 1/) and 
SgI produced by coupled in vitro transcription-translation of 
the cloned SgI eDNA (Bcnedum et al., 1987). These obser- 
vations  indicated  that  mAb 219.6 also recognized the pre- 
trans-Golgi  form of SgI and that the epitope recognized con- 
tained no posttranslationally  modified amino acid residues. 
Third,  immunoprecipitation  of SgI  with  mAb  219.6 was 
equally efficient at pH 7.5 and 6 (Fig.  1, lanes 8 and 9), indi- 
cating that the immunocomplex between Sgl and mAb 219.6 
would not be impaired at the slightly  acidic milieu of the 
trans-Golgi network (Anderson and Pathak,  1985), the site 
of secretory granule formation  (Farquhar and Palade,  1981; 
Orci et al., 1984; Tooze and Tooze, 1986). Fourth, mAb 219.6 
recognized rat SgI after fixation of PC12 cells (not shown) 
and could therefore be used to investigate, by direct immuno- 
fluorescence, whether or not the epitope on SgI was occupied 
by mAb 219.6 expressed in PC12 cells.  Finally,  mAb 219.6 
was an IgG (GI subclass,  r light chain)  rather than an IgM 
(data not shown). We considered this to be an advantage with 
respect to its assembly into a functional antibody in foreign, 
nonlymphoid cells and in terms of its size when used as probe 
in intracellular  transport studies. In view of these properties, 
mAb 219.6 was chosen for expression in PC12 cells. 
Expression and lntracellular Localization of  Anti-SgI 
and Control Antibodies in PC12 Cells 
Poly(A)  ÷ RNA enriched in mRNA coding for the heavy and 
light chains of mAb 219.6 was isolated from the bound poly- 
some fraction of 219.6 hybridoma cells. For control mRNA, 
the poly(A)  + RNA coding for the heavy and light chains of 
mouse mAb PSD4, an antibody recognizing  an epitope on 
the cytoplasmic  domain of VSV-G (Kreis,  1986),  was iso- 
lated from the corresponding hybridoma cells.  As was ex- 
pected, this mAb gave no detectable signal in PC12 cells by 
immunofluorescence  (data  not  shown).  Like  mAb  219.6, 
mAh PSIM belonged to the IgG1 subclass and therefore was 
an appropriate control antibody.  Comparison of the 219.6 
mRNA preparation  (anti-SgI  IgG)  and  the  P5D4  mRNA 
preparation (control, anti-VSV-G IgG) by in vitro translation 
of equal amounts of RNA indicated that the amount of anti- 
body synthesized from the PSD4 mRNA was slightly greater 
than that synthesized from the 219.6 mRNA (data not shown). 
In  the  subsequent microinjection  experiments  with  PC12 
cells, in which the intracellular  transport of anti-SgI IgG and 
control IgG was investigated,  the two mRNA preparations 
were used at identical  RNA concentrations. 
The 219.6 and P5IM mRNAs were introduced  into the 
cytoplasm of PC12  cells by automated,  computer-assisted 
microinjection (Ansorge and Pepperkok,  1988; Pepperkok 
et al.,  1988).  At various time points  after microinjection, 
cells were fixed, and the intracellular  synthesis and transport 
of the anti-SgI IgG and the control IgG were analyzed by im- 
munofluorescence.  To quantitate  the expression and trans- 
port of the two antibodies,  150-600 cells were microinjected 
on each coverslip.  The position of each injected  cell was 
recorded by the computer, permitting  their retrieval after the 
immunofluorescence  procedure. 
Anti-Sgl Antibody. 1.5  h  after microinjection of 219.6 
mRNA into PCl2 cells, immunoreactivity  for the anti-SgI 
IgG was largely observed in the perinuclear area and colocal- 
ized with the Golgi complex, as revealed by double immuno- 
fluorescence using the anti-Golgi antibody of Louvard et al. 
(1982)  (data  not shown).  This indicated  that  antibody ex- 
pressed via mRNA injection  entered the secretory pathway 
in PCI2 cells. 
Fig. 2 shows the intracellular  localization  of the anti-SgI 
IgG 3, 6, and 18 h after microinjection of 219.6 mRNA com- 
pared  with that  of the endogenous SgI, using  double im- 
munofluorescence.  3 h after microinjection, most of the im- 
munoreactivity for the anti-SgI IgG was detected as diffuse 
staining in the perinuclear region, indicating the localization 
of most of the anti-SgI IgG in the Golgi complex (Fig. 2 a). 
In addition,  a minor portion of the immunoreactivity  for the 
anti-SgI IgG was seen in structures with a dotted appearance. 
Some of these punctate structures were present in the periph- 
ery of the cell and were indistinguishable  in position and ap- 
pearance from the secretory granules detected by staining for 
SgI (Fig. 2, a and a'). 6 h after microinjection, only a minor 
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mRNA. PC12 cells were fixed 3 (a and a'), 6 (b and b'), and 18 h (c and c') after microinjection and double immunostained for the localiza- 
tion of anti-SgI IgG (a'-c', tr-Sgl IgG) and for the localization of SgI (a-c, Sgl) using an anti-mouse IgG coupled to rhodamine and using 
an afffinity-purified  rabbit anti-rat SgI antibody (15 ttg/ml) followed by a secondary antibody conjugated to fluorescein, respectively. The 
asterisks indicate the microinjected cells, some of which are polynucleatexl.  The immunostaining for the u-SgI IgG 18 h after microinjection 
is virtually identical to that for SgI. The immunostaining in the Golgi area is often masked by the abundant immunostaining of secretory 
granules (see Fig. 6 for immunoreactivity in the Golgi area after depletion of secretory granules). Bar, 10 #m. 
portion of the immunoreactivity for the anti-SgI IgG was 
found in the perinuclear region where most of it was associated 
with punctate peripheral structures. The pattern of this pe- 
ripheral punctate immunoreactivity for anti-SgI IgG was con- 
mined in the pattern of immunoreactivity for SgI in injected 
cells and constituted a substantial portion of the latter (Fig. 
2, b and b').  18 h after microinjection, the patterns of im- 
munoreactivity for the anti-SgI IgG and SgI itself were al- 
most identical, the pattern for anti-SgI being contained in the 
pattern for SgI and constituting almost all of the latter (Fig. 
2,  c and c'). 
Control Antibody.  Fig. 3 shows the intraceUular localiza- 
tion of the control IgG (anti-VSV-G IgG) 3, 6, and 18 h after 
microinjection of P5D4 mRNA compared with that of the 
endogenous SgI, using double immunofluorescence. At all 
times after microinjection, the patterns of immunoreactivity 
for the control IgG and SgI were clearly distinct.  3 h after 
microinjection, immunoreactivity for the control IgG had a 
Golgi-like pattern (Fig. 3 a') like that observed for the anti- 
SgI IgG (compare Fig. 2 a'). However, in contrast to the lat- 
ter, immunoreactivity for the control IgG gave a Golgi-like 
pattern also 6 and 18 h after microinjection, the intensity be- 
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with P5D4 mRNA. PCI2 cells were fixed 3 (a and a'), 6 (b and b'), and 18 h (c and c') after microinjection and double immunostained 
for the localization of the control antibody (a'-c', ct-VSV-G IgG) and for the localization of SgI (a-c, Sgl) using an anti-mouse IgG con- 
jugated to rhodamine and using an affinity-purified  rabbit anti-rat SgI antibody followed by a secondary antibody conjugated to fluorescein, 
respectively. The asterisks indicate the microinjected cells, some of which are polynucleated. The immunostaining for the c~-VSV-G  IgG 
is largely confined to the perinuclear region and is much less intense 18 h after microinjection. Note the difference in immunostaining 
between SgI and cY-VSV-G IgG at all times after microinjection. Bar, 10/~m. 
ing much less at 18 than at 6 h (Fig. 3, b' and cO. At no time 
point after microinjection did the immunoreactivity for the 
control antibody colocalize with the punctate secretory gran- 
ule staining observed for the endogenous SgI. 
Quantitation.  A  quantitative comparison of the expres- 
sion and intracellular localization of the anti-SgI IgG and the 
control IgG is shown in Table I. After microinjection of ei- 
ther 219.6 or P5D4 mRNA, about half of the injected PC12 
cells transiently synthesized IgG, as indicated by the percent- 
age of IgG-positive cells at 3 h. In the case of the anti-SgI 
IgG, the percentage of IgG-positive cells remained at this 
level from 3 to 18 h. During this time, the immunoreactivity 
for the anti-SgI IgG in the perinuclear area, observed in ev- 
ery IgG-positive cell at 3 h, decreased and concomitantly in- 
creased in peripheral punctate structures, which were stained 
in every IgG-positive cell at 18 h. In contrast, in the case of 
the control IgG, the percentage of  IgG-positive cells decreased 
from 3 to 18 h to about one third of the original value. Here, 
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of  their Intracellular Localization 
Intracellular localization  of lgG 
Diffuse perinuclear immunostaining  Dotted peripheral immunostaining 
lgG-positive  Microinjected  Microinjected 
IgG  Time  microinjected cells  cells  Immunostaining  cells  Immunostaining 
h  %  %  % 
a-SgI IgG  3  55  55  +  +  49  + 
c~-VSV-G IgG  3  56  56  +  +  0  - 
ta-SgI IgG  6  53  45  +  +  53  +  + 
ta-VSV-G IgG  6  40  40  +  +  0  - 
c~-SgI  IgG  18  50  (3)  +  50  +  +  + 
a-VSV-G  IgG  18  18  18  +  0  - 
PCI2 cells were fixed 3, 6, and 18 h after microinjection of either 219.6 or PSD4 mRNA and double immunostained as described in the legends to Figs. 2 and 
3.  lgG-positive cells-i.e., cells immunostained for either anti-SgI lgG (a-SgI IgG) or control IgG (c~-VSV-G IgG)-are expressed as percent of the total cells 
microinjected, as recorded by the computer. IgG-positive cells with diffuse perinuclear immunostaining and dotted peripheral immunostaining are expressed as 
percent of the total cells microinjected. The immunostaining is graded by its intensity as well as by the density of labeled organeUes. Note that the strong dotted 
peripheral immunostaining  for the anti-SgI IgG observed 18 h after microinjection may have masked some of the diffuse perinuclear immunostaining, particularly 
in small cells. Since this may have resulted in an underestimation of the cells showing the latter immunostaining, the corresponding number is given in parenthesis. 
the decrease in perinuclear immunoreactivity  was not ac- 
companied by a concomitant increase in immunoreactivity 
in  other cellular structures.  These results  show that  after 
microinjection  of hybridoma mRNA, PC12 cells synthesized 
and transported  to the Golgi complex both the anti-SgI IgG 
and the control IgG. However, only the anti-SgI IgG, but not 
the control IgG,  was stored in cellular structures  that  ap- 
peared to be secretory granules. 
Colocalization of  Sgl and Anti-Sgl IgG 
by Double Immunofluorescence Using the 
Confocal Microscope 
The apparent identity between the immunofluorescence  pat- 
tern of  endogenous Sgl and that of  the expressed anti-SgI IgG 
seen 18 h after mRNA injection was further investigated us- 
ing the confocal microscope (European Molecular Biology 
Laboratory,  Heidelberg, FRG). This allowed the optical sec- 
tioning of cells with a section thickness  (z-axis) of ,,o0.4 #m 
and a resolution (x/y-plane) of ~0.17/zm,  which is in the 
range  of the diameter of secretory granules  of PC12 cells 
(Greene and Tischler,  1976). Fig.  4 shows the optical sec- 
tioning of a double-immunostained  microinjected PC12 cell 
at five different focal levels. The pattern of secretory granules, 
as revealed by immunostaining  for SgI, was distinct at each 
of the five focal levels. At each focal level, the pattern for the 
expressed anti-SgI IgG was indistinguishable  from that of  en- 
dogenous SgI, indicating colocalization of antibody and anti- 
gen; i.e., the presence of anti-SgI IgG in secretory granules. 
The Control Antibody Is Constitutively Secreted 
from Microinjected  PC12 Cells Whereas the Anti-Sgl 
Antibody Is Stored Intracellularly 
The finding that the intracellular  immunoreactivity  for the 
control IgG after microinjection of P5D4 mRNA was tran- 
sient (Fig. 3) suggested, but did not prove, that this antibody 
was secreted via the constitutive pathway. Likewise, the mas- 
sive accumulation  of anti-SgI IgG in secretory granules after 
microinjection  of 219.6 mRNA (Fig. 2) was consistent with 
the assumption  that most of the newly synthesized  anti-SgI 
IgG was packaged into these storage  organelles.  To inves- 
tigate this biochemically,  PC12 cells microinjected with ei- 
ther P5D4 or 219.6 mRNA were pulse labeled for 1 h with 
[35S]methionine and then chased for 4 h in the presence of 
unlabeled  methionine  (Fig.  5).  Labeled IgG  comigrating 
with unlabeled IgG marker on nonreducing  SDS-PAGE was 
detected after microinjection of either mRNA. After injec- 
tion of 219.6 mRNA, the synthesized anti-SgI IgG was only 
detectable in the cells and not in the medium, whereas after 
injection  of the P5D4 mRNA, the synthesized  control IgG 
was found not only in the cells but also in the medium (Fig. 
5a). However, the ratio of IgG in the medium and cells could 
not be reliably quantitated  from these gels because the IgG 
region of the cell samples also contained other proteins that 
unspecifically absorbed to the anti-IgG-agarose used for im- 
munoprecipitation  (Fig. 5a, compare lanes 219.6 and PSD4 
with lane n.J.). Therefore,  the IgG region of the cell and 
medium samples was reelectrophoresed under reducing con- 
ditions (Fig. 5b,  fluorograms) and the amount of labeled heavy 
chain of either anti-SgI  IgG (219.6) or control IgG (P5D4) 
found in the cells and the medium was quantitated  (Fig. 5b, 
graphs). This indicated that 91% of the pulse-labeled control 
IgG synthesized  after injection  of P5D4 mRNA was found 
in the medium after the 4-h chase, showing that the control 
antibody was indeed constitutively  secreted from PC12 cells 
(Fig.  5b, bottom graphs). In contrast,  ~95 % of the pulse- 
labeled anti-SgI IgG expressed after microinjection  of 219.6 
mRNA into PC12 cells was stored intraceUulary since it was 
found  in  the cells after a  4-h  chase period  (Fig.  5b,  top 
graphs), a time sufficient for the transport of anti-SgI  IgG 
into secretory granules  (cf.  Fig. 2). This high efficiency of 
packaging of the anti-SgI IgG into secretory granules is con- 
sistent with the observation that <90% of pulse-labeled SgI 
is  stored intracellularly  during  this  time  (Tooze,  S.,  and 
W. B. Huttner,  unpublished data). 
As a side observation, we noticed that in the case of anti- 
SgI IgG, the amount of heavy and light chain recovered after 
reducing  SDS-PAGE was less than expected from the inten- 
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Heidelberg,  FRG), showing the colocalization of  anti-SgI IgG and SgI in secretory granules of  a PC12 cell microinjected with 219.6 mRNA. 
PCI2 cells were fixed 18 h after microinjection and double immunostained  for the anti-SgI IgG (a'-e', ot-Sgl IgG, rhodamine) and for SgI 
(a-e, Sgl, fluorescein) as described in Fig. 2. The microinjected cell was scanned in the z-axis at 0.5-/zm steps. The pattern of immunostain- 
ing is shown at five different  focal levels (a and a', 3.5/zm; b and b', 2/~m; c and c',  1.5 #m; d and d', 0.5/~m; e and e', 0 #m  =  level 
of coverslip).  Overlapping of immunoreactivity for SgI and anti-SgI IgG is clearly visible.  Note the noninjected cells,  labeled  only with 
fluorescein,  in the left part of a-e.  Bar,  10/zm. 
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constitutively secreted from microinjected PCI2 cells whereas the 
anti-SgI IgG is stored intracellularly. PC12 cells microinjected with 
mRNA coding for the control antibody (PSD4)  or the anti-SgI anti- 
body (219.6) as well as noninjected PC12 cells (n.i.) were labeled 
for 1 h with [35S]methionine  and then chased for 4 h in the pres- 
ence of unlabeled methionine. At the end of the chase, IgG was im- 
munoprecipitated from the cells and the medium and subjected to 
nonreducing SDS-PAGE (6% polyacrylamide). The IgG region of 
the fluorogram (3.5-d exposure) is shown in a. The position of la- 
beled IgG (arrowheads) was identified by comparison with unla- 
beled IgG which was electrophoresed in adjacent lanes and detected 
by Coomassie blue staining. Note both the IgG band in cells in- 
jected with 219.6 and P5D4 mRNA, but not in noninjected cells, 
and the presence of significant amounts of IgG in the medium only 
after expression of the control antibody (P5D4), but not the anti- 
SgI antibody. (The background in the immunoprecipitates of the 
three cell samples is probably due to both the low amount of ex- 
pressed IgG relative to the endogenous cell proteins and to the fact 
that only 1,000 out of 3,000 PC12 cells were microinjected, only 
50% of which expressed IgG [Table  I]. The dot indicates a cellular 
protein unspecifically precipitated and present in equal amounts in 
all three cell samples.) For quantitation of  the amount of  the control 
IgG and anti-SgI IgG found in the cells and medium at the end of 
the chase, the IgG band was reelectrophoresed under reducing con- 
ditions (12 % polyacrylamide) followed  by fluorography for various 
times (15-31 d), shown for cellular and secreted P5D4 IgG in b on 
the left and right, respectively. The positions of the heavy (H) and 
light (L) chain are indicated. Appropriate fluorograms were used 
for densitometric scanning of  the heavy chain region of  the cell and 
medium samples. For either the anti-SgI  antibody (219.6, top graphs) 
or the control antibody (P5D4, bottom graphs), each of the curves 
shown was constructed from 200 absorbance values determined over 
a length of 8 mm (see abscissa); each of the 200 values per curve 
is expressed as a percent of the total (sum of the 200 absorbance 
values of heavy chain in the cells plus the 200 absorbance values 
of heavy chain in the medium). The absolute amount of total 219.6 
heavy chain recovered after reducing SDS-PAGE  was less than that 
of P5D4 heavy chain, the 219.6 heavy chain in the medium being 
at the limit of detection (see text). 
sity of  the IgG band in the nonreducing gel. A possible expla- 
nation may be that a portion of the anti-SgI IgG is subject 
to limited proteolysis by the secretory granule proteases that 
did not cause a reduced molecular mass of the IgG in non- 
reducing gels because of the presence of intrachain disulfide 
bonds, resulting in the loss of intact heavy and light chains 
upon reduction. 
Regulated Secretion of  Anti-Sgl IgG Induced by 
~-Latrotoxin 
A diagnostic feature that a secretory protein has been pack- 
aged into secretory granules is its exocytosis in response to 
a secretagogue. Regulated secretion of SgI from PC12 can 
be achieved in a calcium-dependent manner by depolariza- 
tion. However, with this (or any other) physiological form 
of stimulation of secretion, only a minor fraction of the to- 
tal  stored  SgI  is  released  from  PC12  cells  (Rosa  et  al., 
1985b), as is the case with other regulated secretory proteins 
(Schweitzer and  Kelly,  1985).  To investigate whether the 
majority of the stored anti-Sgl IgG was subject to regulated 
secretion, we chose as a secretagogue the black widow spi- 
der venom c~-latrotoxin,  which has been shown to induce 
massive exocytosis of secretory granules in PC12 cells (Mel- 
dolesi et al.,  1983;  Watanabe et al.,  1983).  The effect of 
oMatrotoxin on anti-SgI IgG release from PC12 cells was 
studied 18 h after microinjection of 219.6 mRNA by immuno- 
fluorescence. Fig. 6 shows a representative set of PC12 cells 
immunostained for the anti-SgI IgG 18 h after microinjection 
of 219.6 mRNA.  Compared to control cells (Fig.  6, a-d), 
cells exposed to 3 nM oMatrotoxin for 9 min (Fig.  6, e-h) 
showed a drastic reduction in the peripheral punctate staining 
for the anti-SgI IgG, consistent with the exocytotic release of 
the anti-SgI IgG from secretory granules. Interestingly, the 
perinuclear immunoreactivity for the anti-SgI IgG,  which 
was seen in a small proportion of PC12 cells 18 h after micro- 
injection (cf. Table I), was not significantly reduced after ex- 
posure to c~-latrotoxin (Fig. 6f), suggesting that anti-SgI IgG 
still present in the Golgi complex was not affected by the 
secretagogue. 
Specificity of the Subcellular Localization 
of the Anti-SgI lgG 
The  specificity of the  localization of the  anti-SgI  IgG  in 
secretory granules of microinjected PC12 cells was further 
investigated by comparison with another secretory granule 
marker and with markers for other post-Golgi organelles. As 
another secretory granule marker, we studied SgII, another 
matrix protein of many endocrine and neuronal secretory 
granules (Rosa et al., 1985a,b; Cozzi et al., 1989) that is co- 
stored with SgI in secretory granules of PC12 cells (Griiliths, 
G., P. Rosa, and W. B. Huttner, unpublished observations). 
As markers for other post-Golgi organelles, we studied syn- 
aptophysin (p36, p38), an integral membrane protein charac- 
teristic of small synaptic vesicles in the nervous system and 
of related organelles in endocrine cells (Huttner et al., 1983; 
Jahn et al.,  1985; Wiedenmann and Franke,  1985; Navone 
et al., 1986), and lgpl20, a lysosomal and prelysosomal mem- 
brane protein (Lewis et al.,  1985;  Griffiths et al.,  1988). 
Double  immunofluorescence  18  h  after microinjection of 
219.6 mRNA  revealed that the intracellular distribution of 
the anti-SgI IgG and SgII were largely identical (Fig. 7, a and 
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with 219.6 mRNA. 18 h after microinjection of  219.6 mRNA, PCI2 cells were incubated for 9 min in release medium without (a-d, control) 
or with (e-h, c~-Latrotoxin) 3 nM c~-latrotoxin. Cells were then fixed and immunostained with anti-mouse IgG conjugated to rhodamine. 
For each pair of control and c~-latrotoxin-treated  cells (a and e, b and'f, c and g, d and h), the negatives were taken with the same exposure 
and the micrographs were printed under identical conditions. A consistent reduction in intracellular anti-SgI IgG immunoreactivity can 
be observed after stimulation of exocytosis by c~-latrotoxin (compare a-d with e-h).  Bar, 10 #m. 
a), suggesting that the secretory granules containing the anti- 
SgI IgG also contained SglI. In contrast, the intracellular 
distribution of the anti-SgI IgG was clearly distinct from that 
of p38/synaptophysin which was predominantly seen in a 
perinuclear location (Fig.  7, b  and b').  The pattern of im- 
munoreactivity for the anti-SgI IgG was also different from 
that for lgpl20 (Fig. 7, c and d). These results indicated that 
the packaging of the anti-SgI IgG into secretory granules was 
specific with respect to other post-Golgi organelles. 
Anti-Sgl lgG Forms an lmmunocomplex with SgI 
The transport of the anti-SgI IgG, but not of the control anti- 
body, with SgI into secretory granules strongly suggested the 
formation of an immunocomplex between the anti-SgI IgG 
and SgI. To directly demonstrate this, PC12  cells microin- 
jected with mRNA were subjected to reverse immunostain- 
ing; i.e., the detection of expressed functional antibody by 
labeling the fixed and permeabilized cells with exogenous 
antigen (Fig. 8). PC12 cells microinjected with 219.6 mRNA, 
coding  for  anti-SgI  IgG,  were  incubated  with  partially 
purified rat SgI conjugated to rhodamine to investigate whether 
any of the expressed anti-SgI IgG had unoccupied antigen- 
binding sites. As a positive control, PC12 cells microinjected 
with P5D4 mRNA, coding for the control anti-VSV-G  IgG, 
were  incubated with partially purified VSV-G which was 
subsequently detected by a polyclonal antibody against VSV- 
G (Matlin et al.,  1982)  followed by rhodamine-conjugated 
secondary antibody. For both PCI2 cells microinjected with 
219.6 or P5D4 mRNA, the reverse immunostaining obtained 
with exogenous antigen was compared, using double fluores- 
cence, to the normal immunostaining of the expressed anti- 
body obtained with fluorescein-conjugated antibody against 
mouse IgG. Reverse immunostaining with exogenous VSV-G 
as antigen showed the presence of expressed functional con- 
trol antibody in the Golgi area 3 and 6 h after microinjection 
of PC12 cells; the pattern was identical to that observed with 
normal immunostaining (Fig. 8, compare c' and d' with c and 
d).  This indicated that the antigen-binding sites of the ex- 
pressed control antibody were unoccupied, as expected. In 
contrast, no free antigen-binding sites could be detected on 
the expressed  anti-SgI  IgG  since  reverse  immunostaining 
with exogenous SgI as antigen 3 and 18 h after microinjec- 
tion gave no signal over the Golgi area and secretory gran- 
ules,  respectively,  where  the expressed  anti-SgI  IgG  was 
Rosa et al. Rerouting  of Antibody  to Secretory  Granules  27 Figure 7. Immunofluorescence micrographs showing the intracellular  localization  of the ami-SgI IgG in PC12 cells 18 h after microinjection 
of 219.6 mRNA compared with that of SglI, p38/synaptophysin, and lgp120.  PCI2 cells were immunostained for the localization of the 
anti-SgI IgG (a', b', and d, o~SgllgG),  SgII (a), p38/synaptophysin (b, Syn), and lgpl20 (c) using an anti-mouse IgG coupled to rhodamine, 
an altinity-purified rabbit anti-rat SgII antibody (15/~g/ml), a mouse monoclonal anti-rat p38/synaptophysin antibody (30/~g/ml), and 
a rabbit anti-rat 1gp120 antiserum (1:500 dilution), respectively, followed by appropriate secondary antibodies conjugated to fluorescein 
(a and b) or rhodamine (c). a and a' and b and b' are double-immunofluorescence  micrographs; c and d are different coverslips. The asterisks 
indicate the microinjected cells, some of which are polynucleated. The intracellular localization of the anti-SgI antibody is very similar 
to that of SglI (a and a') but quite distinct from the largely perinuclear localization of p38/synaptophysin (b and b') and lgpl20 (c and 
d). Bar,  10 t~m. 
The Journal of Cell Biology,  Volume 109, 1989  28 Figure 8. Reverse immunostaining  showing the presence of an immunocomplex between  SgI and the anti-SgI antibody in PCI2 cells after 
microinjection of 219.6 mRNA. PCI2 cells were fixed 3 (a and a') and 18 h (b and b') after microinjection of 219.6 mRNA (PC12 expressing 
a-Sgl lgG) and double immunostained using partially  purified  SgI conjugated to rhodamine (a' and b') to search for free antigen-binding 
sites on the expressed  anti-SgI IgG (reverse  immunostaining),  and using an anti-mouse IgG antibody conjugated  to fluorescein  (a and b) 
to detect the expressed  anti-SgI IgG. As a control, 219.6 hybridoma cells (e and f, 219.6 Hy, two different coverslips)  were immunostained 
using the partially purified  SgI conjugated to rhodamine (f) or an anti-mouse IgG antibody conjugated to rhodamine (e).  PC12 cells were 
fixed 3 (c and c') and 6 h (d and d') after microinjection of P5D4 mRNA (PC12 expressing ct-VSIZ-G IgG) and double immunostained 
using partially purified  VSV-G followed by polyclonal rabbit anti-VSV-G antibody and a secondary antibody conjugated to rhodamine (c' 
and d') to demonstrate the presence of free antigen-binding  sites on the expressed  control antibody (reverse  immunostaining)  and using 
an anti-mouse IgG antibody coupled to fluorescein  (c and d) to detect the expressed  control antibody. As a control, P5D4 hybridoma cells 
(g and h, P5D4 Hy, two different coverslips) were immunolabeled using the partially  purified VSV-G followed by the polyclonal anti-VSV-G 
antibody and rhodamine-conjugated secondary antibody (h) or an anti-mouse IgG antibody conjugated to rhodamine (g). Note the absence 
and presence of free antigen-binding  sites on the expressed  anti-SgI IgG (a' and b') and control antibody (c' and d'), respectively.  The 
pattern ofimmunostaining for the free antigen-binding  sites on the expressed control antibody (c' and d') overlaps with that for the expressed 
antibody (c and d).  Bar,  10 #m. 
Rosa et al. Rerouting of Antibody to Secretory Granules  29 Figure 9. Double-immunofluorescence micrographs showing the effect of ammonium chloride on the intracellular accumulation of anti-SgI 
IgG in NGF-differentiated PCI2 cells microinjected with 219.6 mRNA. NGF-differentiated PC12  cells microinjected with 219.6 mRNA 
were incubated for 18 h without (a, a', and a", Control) or with (b, b', and b", Ammonium  chloride)  10 mM NH4CI.  Cells were fixed and 
double immunostained for the localization of anti-SgI IgG (a" and b", c~-Sgl IgG) and of SgI (a' and b') using an anti-mouse IgG conjugated 
to rhodamine and using an afffinity-purified rabbit anti-rat SgI antibody followed by a secondary antibody conjugated to fluorescein, respec- 
tively, a and b show Nomarski photographs of the corresponding fields. The asterisks indicate the microinjected cells, some of which are 
polynucleated. In control cells, dotted immunostaining for both SgI and anti-SgI IgG is observed in the perikaryon, along the cell processes, 
and in the tips of the processes (a, a', a", arrowheads).  In ammonium chloride-treated cells, dotted immunostaining in the perikaryon and 
cell processes is observed only for SgI, whereas the immunostaining for the anti-SgI IgG is more diffuse and perinuclear, and little, if 
any, anti-SgI IgG appears to accumulate in the periphery of the perikaryon and in the tips of the cell processes (b, b', b", arrowheads). 
Bar,  10 #m. localized as  revealed by normal  immunostaining (Fig.  8, 
compare a' and b' with a  and b). 
As another positive control, 219.6 hybridoma cells, which 
express anti-SgI IgG but not SgI, were subjected to reverse 
immunostaining with exogenous SgI as antigen. This demon- 
strated  that  reverse  immunostaining  with  exogenous  SgI 
allowed the detection of intracellular anti-SgI IgG with un- 
occupied antigen-binding sites (Fig. 8f). The reverse immu- 
nostaining of 219.6 hybdridoma cells was similar in pattern 
and intensity to the reverse immunostaining obtained with 
exogenous VSV-G as antigen in P5D4 hybridoma cells, which 
express anti-VSV-G  IgG (Fig. 8 h). 
The lack of free antigen-binding sites on the anti-SgI IgG 
expressed in PC12  cells was, therefore, most probably due 
to the occupancy of these sites by endogenous SgI. This sug- 
gested that the endogenous SgI was produced in excess over 
the expressed anti-SgI IgG. This conclusion was supported 
by two observations (data not shown). First, mAb 219.6 con- 
jugated to rhodamine was used in immunofluorescence of 
PC12 cells microinjected with 219.6 mRNA to label the en- 
dogenous SgI via the same epitope that was the target for the 
expressed anti-SgI IgG. This showed only a small and vari- 
able  decrease  in  the  rhodamine fluorescence in  microin- 
jected cells compared with noninjected cells, suggesting that 
the amount of expressed anti-SgI IgG was only sufficient to 
bind to a portion of the newly synthesized SgI. Second, the 
amount of radioactive SgI and radioactive IgG synthesized 
during a  1-h  pulse  with  [3sS]methionine  was  quantitated. 
This, together with the fact that one third of the cells were 
microinjected, '~50% of which expressed IgG (Table I), al- 
lowed us to estimate that labeled SgI exceeded labeled IgG 
at least fivefold in microinjected, antibody-expressing PC12 
cells. 
Packaging of  Anti-Sgl IgG Is Blocked by 
Ammonium Chloride 
Drugs that neutralize the acidic pH of intracellular organ- 
elles,  such  as  ammonium chloride  and  chloroquine,  are 
thought to inhibit the packaging of regulated secretory pro- 
teins into secretory granules and to divert them to the consti- 
tutive pathway of secretion in AtT-20 cells (Moore et al., 
1983).  Consistent with this notion is the observation that in 
PC12  cells treated with ammonium chloride, a substantial 
portion of the newly synthesized SgI and SgII is secreted 
without stimulation of exocytosis (Tooze,  S.,  P.  Rosa,  P. 
Baeuerle, and W. B. Huttner, unpublished data). It was there- 
fore of interest to investigate whether the packaging of the 
anti-SgI IgG was affected when PC12  cells microinjected 
with 219.6 mRNA were treated with ammonium chloride. 
For these experiments, PC12  cells were differentiated with 
NGF to stimulate the outgrowth of neurite-like processes. 
This facilitated the distinction between the Golgi complex, 
which remains confined to the perikaryon, and mature secre- 
tory granules, which are transported to the tips of the cell 
processes.  In NGF-differentiated PC12  cells incubated for 
18 h after microinjection of 219.6 mRNA in the absence of 
ammonium chloride, the anti-SgI IgG was observed in the 
perinuclear Golgi region, in punctate structures that were 
found throughout the perikaryon, and in the cell processes 
where they appeared to be concentrated in the tips (Fig. 9 
a"). As in undifferentiated PC12 cells, this punctate pattern 
overlapped with a major portion of the pattern of secretory 
granules immunostained for the endogenous SgI (Fig. 9 a'). 
When  NGF-differentiated PC12  cells  were  incubated  for 
18 h after microinjection of 219.6 mRNA in the presence of 
ammonium chloride, the perinuclear staining for the anti-SgI 
IgG was still observed, whereas the punctate staining for the 
anti-SgI IgG at the periphery of the perikaryon and in the tips 
of the cell processes was hardly detectable (Fig. 9 b"). Am- 
monium chloride treatment also partically reduced the punc- 
tate immunostaining for the endogenous SgI at the periphery 
of the perikaryon and in the tips of the cell processes, but not 
the perinuclear staining in the Golgi area (Fig. 9 b'). These 
results were consistent with the interpretation that (a) in the 
presence of ammonium chloride, a major portion of the newly 
synthesized SgI, and the anti-SgI IgG bound to it, were not 
packaged into secretory granules but diverted to transport 
vesicles of the constitutive secretory pathway that were not 
detected under the present experimental conditions; and (b) 
the SgI-immunoreactive structures seen in the tips of the cell 
processes after ammonium chloride treatment represented 
secretory granules that had been  formed before the drug 
treatment. 
Discussion 
Rerouting of  a Constitutive Secretory Protein 
to Secretory Granules by Protein-Protein Interaction 
with a Regulated Secretory Protein 
We have shown that a constitutive secretory protein can be 
diverted to the regulated pathway of secretion by interacting 
noncovalently with a regulated secretory protein. This con- 
clusion is supported by several  lines of evidence. First, the 
constitutive secretory protein chosen, a monoclonal anti-SgI 
antibody, was specifically packaged into secretory granules, 
as indicated by (a) its colocalization with SgI and SgII, two 
established secretory granule markers (Rosa et al.,  1985a, 
b), in double immunofluorescence using the conventional as 
well as the confocal microscope; (b) its virtually complete 
intracellular storage in pulse-chase experiments; (c) its re- 
lease from PC12 cells after stimulation of exocytosis of se- 
cretory granules by c~-latrotoxin; and (d) its absence from 
other post-Golgi organelles such as prelysosomes, lysosomes, 
and small synaptic vesicles. Second, the packaging of this 
constitutive secretory protein into secretory granules was the 
consequence of its noncovalent interaction with a regulated 
secretory protein via the formation of an immunocomplex, 
since (a) a control antibody of the same IgG subclass was not 
packaged into secretory granules but was secreted constitu- 
tively; (b) the antigen-binding sites on the anti-SgI antibody 
were occupied by endogenous antigen; and (c) diversion of 
the antigen, SgI, to the constitutive pathway by ammonium 
chloride treatment of cells also prevented packaging of the 
anti-SgI antibody into secretory granules. 
These results provide direct evidence that the targeting in- 
formation contained in  a  regulated  secretory protein  can 
dominate over the post-Golgi secretory route usually taken 
by a  constitutive secretory protein.  Our  observations are 
consistent with the results of Moore and Kelly (1986),  who 
studied the intracellular transport of a chimeric fusion pro- 
tein composed of a polypeptide hormone and the ectodomain 
of a viral membrane protein, and extend their conclusion to 
an intact constitutive secretory protein unaltered by genetic 
engineering. Moreover, as far as we are aware, our data pro- 
vide the first evidence for the rerouting of a newly synthe- 
sized protein by a noncovalent protein-protein interaction. 
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Figure  10.  Scheme  illustrating 
three possible mechanisms for the 
sorting of SgI to secretory gran- 
ules of PC12 cells as well as the 
rerouting of the anti-SgI IgG and 
its implications. The symbols used 
in the scheme are shown enlarged 
on the bottom and are from left to 
right: SgI with epitope recognized 
by mAb 219.6 (triangular side of 
square) and a putative sorting sig- 
nal (semicircular  s/de); mAb 219.6 
(anti-SgI IgG) expressed  by micro- 
injection of 219.6 mRNA; mAb 
P5D4 (anti-VSV-G IgG) expressed 
by microinjection  of  P5D4 mRNA; 
and putative receptors recogniz- 
ing either a sorting signal on non- 
aggregated SgI (left symbol) or a 
specific feature of aggregated SgI 
(right symbol). In the first mech- 
anism (arrow 1), receptors have 
to recycle for reasons of stoichi- 
ometry  (dashed upward line), 
whereas, in the second (arrow 2) 
and third mechanisms (arrow 3), 
receptors may or may not recycle. 
Note that in the second and third 
mechanisms, an epitope (such as 
219.6) recognized by an antibody 
diverted to secretory  granules may 
nevertheless be involved in sort- 
ing and aggregation unless the an- 
tibody is expressed in excess of 
the antigen. SG, Secretory gran- 
ules; CV, constitutive vesicle. 
Implications for the Sorting of Regulated 
Secretory Proteins 
At least three mechanisms can be envisaged to explain the 
sorting of regulated secretory proteins from constitutive se- 
cretory proteins, their aggregation, and their packaging into 
secretory granules (Fig. 10; Burgess and Kelly, 1987; Pfeffer 
and Rothman,  1987). In the first mechanism (Fig.  10, left), 
it is assumed that regulated secretory proteins contain sort- 
ing signals in the form of specific linear sequences or confor- 
mational epitopes and are sorted from constitutive secretory 
proteins by a receptor-mediated mechanism to a compartment 
where they aggregate (e.g., a specific region of the trans Golgi 
network or condensing vacuole) followed by their packaging 
into secretory granules. In the second mechanism (Fig.  10, 
middle),  it is assumed that regulated secretory proteins seg- 
regate  from constitutive secretory proteins  in  a  receptor- 
independent process by their intrinsic ability to form ag- 
gregates,  either  with  themselves or  with  other  regulated 
secretory proteins, which are then packaged into secretory 
granules by a mechanism involving the recognition of some 
feature of the aggregate by a receptor (Huttner et al., 1988). 
In the third mechanism (Fig. 10, right), which combines fea- 
tures of the first two mechanisms, it is assumed that a portion 
of the regulated secretory proteins specifically interact with 
a receptor, which triggers the formation of an aggregate of 
regulated secretory proteins that excludes constitutive secre- 
tory proteins, followed by packaging into secretory granules. 
The implications of the present data for these possible 
sorting and aggregation mechanisms are illustrated in Fig. 
10. If SgI is sorted by the first mechanism, the epitope on 
SgI occupied by mAb 219.6 cannot be the sorting signal rec- 
ognized by the receptor (Fig. 10, left). However, such a sort- 
ing signal could be identified in SgI, or any other regulated 
secretory protein, by searching for an rnAb that, when ex- 
pressed in cells, interferes with the sorting. This immunolog- 
ical approach to  studying secretory protein sorting could 
complement the  genetic  engineering  approach.  If SgI  is 
sorted by the second mechanism, the 219.6 epitope may or 
may not be involved in the recognition of the aggregate by 
the receptor since (a) the aggregate contains more potential 
receptor-binding sites than there are receptors; and since (b) 
the amount of antibody expressed in the present conditions 
was at most 20% of that of newly synthesized SgI and thus 
not sufficient to occupy the 219.6 epitope of  all newly synthe- 
sized SgI molecules (Fig.  10, middle).  Such a binding site 
could be identified in SgI, or any other regulateat  secretory 
protein, using the approach of antibody expression, provided 
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newly synthesized regulated secretory protein. Interestingly, 
overexpression of an anti-SgI IgG could also be a means of 
investigating  the biological  significance  of the aggregation 
step since we find it unlikely that aggregation of SgI would 
proceed  normally  if all  newly  synthesized  SgI  molecules 
were complexed to an antibody. If SgI is sorted by the third 
mechanism,  the 219.6 epitope again may or may not be in- 
volved in the interaction with the receptor,  since under the 
present conditions a sufficient number of newly synthesized 
SgI molecules uncomplexed to anti-SgI IgG were available 
to bind to the receptor and to initiate the aggregation (Fig. 
10,  right). 
Implications for Functional Studies 
on Secretory Granules 
The  finding  that antibodies  can be diverted  into secretory 
granules opens new ways of studying secretory granule func- 
tions. Antibodies have proven to be powerful tools for study- 
ing cell-cell  interactions,  as well as intracellular function, 
when applied to the outside of cells (e.g., Miiller and Gerisch, 
1978)  or microinjected  into the cytoplasm  (e.g.,  Mabuchi 
and Okuno, 1977). Given the results of the present study and 
using more efficient expression systems than microinjection 
of hybridoma mRNA, it should in principle be possible, by 
using expressed antibodies as tools, to study the function of 
any epitope exposed on the luminal side of secretory gran- 
ules, be it on a granule matrix or membrane protein. For ex- 
ample, the organization of the granule matrix, the processing 
of prohormones, and the role of ion pumps and other trans- 
membrane  transport systems  could be  investigated  by this 
immunological  approach.  Moreover,  antibodies  that block 
the transport of specific proteins into secretory granules could 
be used to generate granules selectively depleted of these pro- 
teins. Finally, one may think of expressing chimeric antibod- 
ies to cross-link  secretory proteins and study the functional 
consequences. 
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